{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T21:14:51Z","timestamp":1767993291191,"version":"3.49.0"},"reference-count":82,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2015,11,4]],"date-time":"2015-11-04T00:00:00Z","timestamp":1446595200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Haemophilia"],"published-print":{"date-parts":[[2016,3]]},"abstract":"<jats:p>The management of pain and inflammation in haemophilic arthropathy is challenging due to the lack of anti\u2010inflammatory analgesic agents perfectly suitable for this population. Non\u2010steroidal anti\u2010inflammatory drugs (<jats:styled-content style=\"fixed-case\">NSAID<\/jats:styled-content>s) are widely used in the management of arthritis due to their analgesic and anti\u2010inflammatory effects. Their use in persons with haemophilia (<jats:styled-content style=\"fixed-case\">PWH<\/jats:styled-content>), however, is limited due to increased risk of bleeding mainly from the upper gastrointestinal (<jats:styled-content style=\"fixed-case\">UGI<\/jats:styled-content>) tract. Cyclooxygenase\u20102 (<jats:styled-content style=\"fixed-case\">COX<\/jats:styled-content>\u20102) selective <jats:styled-content style=\"fixed-case\">NSAID<\/jats:styled-content>s which have comparable analgesic effect to traditional <jats:styled-content style=\"fixed-case\">NSAID<\/jats:styled-content>s (<jats:styled-content style=\"fixed-case\">tNSAID<\/jats:styled-content>s) but with less <jats:styled-content style=\"fixed-case\">UGI<\/jats:styled-content> bleeding have been considered to be a suitable option for treatment of haemophilic arthropathy. <jats:styled-content style=\"fixed-case\">COX<\/jats:styled-content>\u20102 inhibitors, however, have an increased in the risk of cardiovascular (<jats:styled-content style=\"fixed-case\">CV<\/jats:styled-content>) disease. Although the atherosclerotic burden in <jats:styled-content style=\"fixed-case\">PWH<\/jats:styled-content> is similar to that in the general population, the risk of <jats:styled-content style=\"fixed-case\">CV<\/jats:styled-content>\u2010related deaths is lower. <jats:styled-content style=\"fixed-case\">PWH<\/jats:styled-content> have a higher risk of <jats:styled-content style=\"fixed-case\">GI<\/jats:styled-content> bleeding and lower risk of thrombotic disease compared to general population. Therefore, when <jats:styled-content style=\"fixed-case\">PWH<\/jats:styled-content> require anti\u2010inflammatory\/analgesic agents, it seems reasonable to use lowest dose of <jats:styled-content style=\"fixed-case\">COX<\/jats:styled-content>\u20102 inhibitors for the shortest period together with a proton pump inhibitor. <jats:italic>Helicobacter pylori<\/jats:italic> infection should be tested for and eradicated prior to starting <jats:styled-content style=\"fixed-case\">NSAID<\/jats:styled-content> treatment in <jats:styled-content style=\"fixed-case\">PWH<\/jats:styled-content>. Furthermore, regular blood pressure and renal function test monitoring is required during <jats:styled-content style=\"fixed-case\">COX<\/jats:styled-content>\u20102 inhibitor treatment.<\/jats:p>","DOI":"10.1111\/hae.12805","type":"journal-article","created":{"date-parts":[[2015,11,5]],"date-time":"2015-11-05T03:29:44Z","timestamp":1446694184000},"page":"179-187","source":"Crossref","is-referenced-by-count":21,"title":["Choosing and using non\u2010steroidal anti\u2010inflammatory drugs in haemophilia"],"prefix":"10.1111","volume":"22","author":[{"given":"D. R. J.","family":"Arachchillage","sequence":"first","affiliation":[{"name":"Sheffield Haemophilia and Thrombosis Centre Royal Hallamshire Hospital Sheffield UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Makris","sequence":"additional","affiliation":[{"name":"Sheffield Haemophilia and Thrombosis Centre Royal Hallamshire Hospital Sheffield UK"},{"name":"Department of Cardiovascular Science University of Sheffield Sheffield UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2015,11,4]]},"reference":[{"key":"e_1_2_3_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2006.01208.x"},{"key":"e_1_2_3_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2010.02287.x"},{"key":"e_1_2_3_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07386.x"},{"key":"e_1_2_3_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-07-215665"},{"key":"e_1_2_3_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.12006"},{"key":"e_1_2_3_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2007.01453.x"},{"key":"e_1_2_3_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200108093450607"},{"key":"e_1_2_3_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2012.02909.x"},{"key":"e_1_2_3_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2012.02808.x"},{"key":"e_1_2_3_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.12349"},{"key":"e_1_2_3_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-012-1386-3"},{"key":"e_1_2_3_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.27412"},{"key":"e_1_2_3_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c7086"},{"key":"e_1_2_3_15_1","doi-asserted-by":"publisher","DOI":"10.1080\/07853890902887295"},{"key":"e_1_2_3_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.12855"},{"key":"e_1_2_3_17_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1351-8216.2003.00821.x"},{"key":"e_1_2_3_18_1","doi-asserted-by":"publisher","DOI":"10.5847\/wjem.j.1920-8642.2011.01.001"},{"key":"e_1_2_3_19_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e3412"},{"key":"e_1_2_3_20_1","doi-asserted-by":"publisher","DOI":"10.3109\/00365529509093304"},{"key":"e_1_2_3_21_1","first-page":"685","article-title":"Critical issues in the pathophysiology and management of peptic ulcer disease","volume":"7","author":"Hunt RH","year":"1995","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"e_1_2_3_22_1","doi-asserted-by":"publisher","DOI":"10.1586\/ecp.11.36"},{"key":"e_1_2_3_23_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.106.105569"},{"key":"e_1_2_3_24_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI27291"},{"key":"e_1_2_3_25_1","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1177\/009127000004001005","article-title":"Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX\u20102 versus COX\u20101 in healthy volunteers","volume":"40","author":"Van HA","year":"2000","journal-title":"J Clin Pharmacol"},{"key":"e_1_2_3_26_1","first-page":"804","article-title":"A metaanalysis of severe upper gastrointestinal complications of nonsteroidal antiinflammatory drugs","volume":"29","author":"Ofman JJ","year":"2002","journal-title":"J Rheumatol"},{"key":"e_1_2_3_27_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar4178"},{"key":"e_1_2_3_28_1","unstructured":"Oxford League Table of Analgesics in Acute Pain. Bandolier Web site. Available athttp:\/\/www.jr2.ox.ac.uk\/bandolier\/booth\/painpag\/Acutrev\/Analgesics\/Leagtab.html. Accessed August 11 2015."},{"key":"e_1_2_3_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2007.03.011"},{"key":"e_1_2_3_30_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar4174"},{"key":"e_1_2_3_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF03261999"},{"key":"e_1_2_3_32_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keh627"},{"key":"e_1_2_3_33_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001098"},{"key":"e_1_2_3_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2014.04.012"},{"key":"e_1_2_3_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2003.10.040"},{"key":"e_1_2_3_36_1","first-page":"13","article-title":"Safe prescribing of non\u2010steroidal anti\u2010inflammatory drugs in patients with osteoarthritis \u2010 an expert consensus addressing benefits as well as gastrointestinal and cardiovascular risks","volume":"19","author":"Scarpignato C","year":"2015","journal-title":"BMC Med"},{"key":"e_1_2_3_37_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2011.480"},{"key":"e_1_2_3_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2004.01898.x"},{"key":"e_1_2_3_39_1","unstructured":"NICE guidelines.Dyspepsia and gastrooesophageal reflux disease: Investigation and management of dyspepsia symptoms suggestive of gastrooesophageal reflux disease or both. September2014."},{"key":"e_1_2_3_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.gtc.2010.08.010"},{"key":"e_1_2_3_41_1","first-page":"63","article-title":"Prevention and treatment of non\u2010steroidal anti\u2010inflammatory drug\u2010induced gastro\u2010duodenal damage: rationale for the use of antisecretory compounds","volume":"31","author":"Scarpignato C","year":"1999","journal-title":"Ital J Gastroenterol Hepatol"},{"key":"e_1_2_3_42_1","doi-asserted-by":"publisher","DOI":"10.3310\/hta10380"},{"key":"e_1_2_3_43_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2009.115"},{"key":"e_1_2_3_44_1","first-page":"338","article-title":"A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID\u2010associated Ulcer Treatment (ASTRONAUT) Study Group","volume":"12","author":"Yeomans ND","year":"1998","journal-title":"N Engl J Med"},{"key":"e_1_2_3_45_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199803123381105"},{"key":"e_1_2_3_46_1","first-page":"503","article-title":"Gastrointestinal bleeding in haemophilia","volume":"42","author":"Forbes CD","year":"1973","journal-title":"Q J Med"},{"key":"e_1_2_3_47_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2005.41833.x"},{"key":"e_1_2_3_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(85)90515-3"},{"key":"e_1_2_3_49_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.2830470425"},{"key":"e_1_2_3_50_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V61.4.709.709"},{"key":"e_1_2_3_51_1","first-page":"204","article-title":"Non\u2010steroidal anti\u2010inflammatory drugs in haemophilic arthritis. A clinical and laboratory study","volume":"15","author":"Steven MM","year":"1985","journal-title":"Haemostasis"},{"key":"e_1_2_3_52_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2257.1984.tb00529.x"},{"key":"e_1_2_3_53_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2006.01311.x"},{"key":"e_1_2_3_54_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-7843.2006.pto_248.x"},{"key":"e_1_2_3_55_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.167.4.394"},{"key":"e_1_2_3_56_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.162.19.2204"},{"key":"e_1_2_3_57_1","doi-asserted-by":"publisher","DOI":"10.1096\/fj.07-8506com"},{"key":"e_1_2_3_58_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2011.02567.x"},{"key":"e_1_2_3_59_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23161"},{"key":"e_1_2_3_60_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-5378.1998.08052.x"},{"key":"e_1_2_3_61_1","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1055\/s-0037-1613581","article-title":"Helicobacter pylori causes gastrointestinal hemorrhage in patients with congenital bleeding disorders","volume":"89","author":"Schulman S","year":"2003","journal-title":"Thromb Haemost"},{"key":"e_1_2_3_62_1","unstructured":"EMA.European Medicine Agency concludes action on COX\u20102 inhibitors. June2005."},{"key":"e_1_2_3_63_1","unstructured":"EMA.European Medicines Agency review concludes positive benefit\u2010risk balance for non\u2010selective NSAIDs. October2006."},{"key":"e_1_2_3_64_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.332.7553.1302"},{"key":"e_1_2_3_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2006.07.069"},{"key":"e_1_2_3_66_1","doi-asserted-by":"publisher","DOI":"10.1258\/jrsm.99.3.132"},{"key":"e_1_2_3_67_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.108.764530"},{"key":"e_1_2_3_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60503-1"},{"key":"e_1_2_3_69_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2004.12.005"},{"key":"e_1_2_3_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(12)80155-7"},{"key":"e_1_2_3_71_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/34.2.162"},{"key":"e_1_2_3_72_1","doi-asserted-by":"publisher","DOI":"10.18433\/J3VW2F"},{"key":"e_1_2_3_73_1","unstructured":"Celebrex 200 mg capsule.Summary of Product Characteristics Last Updated on eMC 11\u2010Dec\u20102014."},{"key":"e_1_2_3_74_1","doi-asserted-by":"publisher","DOI":"10.1160\/TH12-05-0313"},{"key":"e_1_2_3_75_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2011.04542.x"},{"key":"e_1_2_3_76_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-453159"},{"key":"e_1_2_3_77_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.20339"},{"key":"e_1_2_3_78_1","first-page":"437","article-title":"Mortality among males with hemophilia: relations with source of medical care. The Hemophilia Surveillance System Project Investigators","volume":"96","author":"Soucie JM","year":"2000","journal-title":"Blood"},{"key":"e_1_2_3_79_1","first-page":"25","article-title":"Risk of stroke associated with nonsteroidal anti\u2010inflammatory drugs","volume":"10","author":"Park K","year":"2014","journal-title":"Vasc Health Risk Manag"},{"key":"e_1_2_3_80_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2005.080754"},{"key":"e_1_2_3_81_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2010.04495.x"},{"key":"e_1_2_3_82_1","unstructured":"Based on QRisk2 calculator. Available athttp:\/\/www.qrisk2.org. Accessed October 5 2015."},{"key":"e_1_2_3_83_1","first-page":"207","article-title":"The effect of haemophilia and von Willebrand disease on arterial thrombosis: a systematic review","volume":"68","author":"Biere\u2010Rafi S","year":"2010","journal-title":"Neth J Med"}],"container-title":["Haemophilia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fhae.12805","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hae.12805","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T13:15:29Z","timestamp":1695561329000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hae.12805"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,4]]},"references-count":82,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["10.1111\/hae.12805"],"URL":"https:\/\/doi.org\/10.1111\/hae.12805","archive":["Portico"],"relation":{},"ISSN":["1351-8216","1365-2516"],"issn-type":[{"value":"1351-8216","type":"print"},{"value":"1365-2516","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11,4]]}}}